27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Morgan Stanley’s David N. Lebowitz expects Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares to remain range bound, following the announcement by the company that it was discontinuing its Revusiran program.
Lebowitz downgraded the rating on the company from Overweight to Equal Weight, while lowering the price target from $93 to $36.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Program Failure
“Alnylam recently announced that they were discontinuing the revusiran program after the Data Monitoring Committee (DMC) determined during an interim analysis that the benefit-risk profile of the therapy does not support further investigation,” the analyst explained.
However, Lebowitz pointed out that the extensive dataset for the company’s Patisiran program suggests that the drug was likely to be approved and was expected to reach the market by 2018.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
“In addition, while risks have no doubt increased, the company has an extensive pipeline that provides some level of a valuation backstop for shares,” the analyst stated.
Overhang On Stock
Lebowitz believes that until Alnylam Pharma is able to provide more details on whether the failure of the Revusiran program was due to drug-, platform- or TTR-specific issues, this event is likely to lead to an overhang on the shares.
The analyst also believes that “clean data from the PhIII APOLLO trial for patisiran which is to be released mid 2017 as well as PhI data for ALN-TTRsc02 is likely necessary for the overhang to dissipate.”
At last check, Alnylam was down 5.41 percent at $34.25.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.